Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04006288 · ClinicalTrials.gov registry record · Phase 4
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
A Phase 4 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT04006288 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 90 participants.
The verdict
NCT04006288, a Phase 4 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations. The objectives of this investigation are to assess the feasibility of switching from a DAPT to DPI regimen and to compare the pharmacodynamic profiles of these treatment regimens. This will be a prospective study conducted in cohorts of patients with CAD on treatment per standard of care with DAPT. Patients will be randomized to either maintain DAPT or to DPI. DPI consists in treatment with aspirin (81mg/qd) plus rivaroxaban (2.5mg/bid).
Interventions
- DRUG Clopidogrel
- DRUG Prasugrel
- DRUG aspirin
- DRUG ticagrelor
- DRUG rivaroxaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2019-09-06 |
| Est. Completion | 2022-05-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04006288
The ClinicalTrials.gov registry entry for NCT04006288 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Clopidogrel is the first listed.
NCT04006288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04006288 about?
NCT04006288 is a clinical study titled "Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease". Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations. The objectives of this investigation are to assess the feasibility of switching from a DAPT to DPI regime...
What is the current status of trial NCT04006288?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2019-09-06. Estimated completion is 2022-05-16.
What interventions are being tested in trial NCT04006288?
The interventions under investigation include: Clopidogrel (DRUG), Prasugrel (DRUG), aspirin (DRUG), ticagrelor (DRUG), rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT04006288?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.